The Technical Analyst
Kadmon Holdings Inc [KDMN]
Exchange: NYSE Sector: Healthcare Industry: Biotechnology
Kadmon Holdings Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $9.50
America/New_York / 31 des 1970 @ 19:00
| RATING 2022-01-31 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -13.32 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.33x |
| Company: PE -13.32 | industry: PE 40.47 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 9.29 - 9.71 ( +/- 2.24%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-11-09 | Waksal Harlan | Sell | 177 945 | Common Stock |
| 2021-11-09 | Waksal Harlan | Buy | 655 000 | Stock Appreciation Right |
| 2021-11-09 | Waksal Harlan | Buy | 982 500 | Performance Stock Option(right to buy) |
| 2021-11-09 | Waksal Harlan | Buy | 1 350 000 | Stock Option (right to buy) |
| 2021-11-09 | Waksal Harlan | Buy | 2 000 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 0.00 |
| Last 93 transactions |
| Buy: 16 325 233 | Sell: 4 159 124 |
Forecast:
01:40 - $10.17
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.50 (0.00% ) |
| Volume | 10.42 mill |
| Avg. Vol. | 10.03 mill |
| % of Avg. Vol | 103.90 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KDMN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
KDMN
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.
Latest Press Releases
2021-11-09 09:05:00 - Press Release
Sanofi Completes Acquisition Of Kadmon
Sanofi completes acquisition of kadmon
2021-11-04 08:00:00 - Press Release
Kadmon Provides Business Update And Reports Third Quarter 2021 Financial Results
- rezurock™ (belumosudil) 200 mg once daily (qd) tablets are now commercially available for shipment to prescribed patients in the united states - - execution of strategic launch strategy underway; third quarter rezurock net sales $12.2 million - - sanofi acquisition of kadmon expected to close 4q 2021 - new york, ny / accesswire / november 4, 2021 / kadmon holdings, inc. (nasdaq:kdmn) today provided a business update and reported financial and operational results for the third quarter of 2021. "the third quarter was an exceptional period for kadmon culminating in the availability of rezurock to patients living with cgvhd and the significant milestones that were achieved in the months following our strategic commercial launch," said harlan w.
2021-10-01 08:01:00 - Press Release
Kadmon Announces Abstracts Accepted For Presentation At The Society For Immunotherapy Of Cancer's 36th Annual Meeting
New york, ny / accesswire / october 1, 2021 / kadmon holdings, inc. (nasdaq:kdmn) today announced it will present data from the ongoing phase 1 clinical trial of kd033, its anti-pd-l1/il-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other il-15 preclinical work, at the society for immunotherapy of cancer's (sitc 2021) 36th annual meeting, taking place virtually november 10 - 14, 2021. details of the presentations are outlined below.
2021-09-30 18:20:00 - Press Release
Shareholder Alert: Weisslaw Llp Reminds Cxp, Jmp, Echo, And Kdmn Shareholders About Its Ongoing Investigations
New york, sept. 30, 2021 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq.
2021-09-21 19:46:00 - Press Release
Kadmon Holdings Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Kadmon Holdings, Inc. - Kdmn
New orleans, sept. 21, 2021 /prnewswire/ -- former attorney general of louisiana charles c.
Latest News
2021-10-05 07:39:00 - The Motley Fool
3 Biotech Stocks That Surged in September
2021-10-01 08:01:00 - Accesswire
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-15 preclinical work, at the Society for Immunotherapy of Cancer's (SITC 2021) 36th Annual Meeting, taking place virtually November 10 - 14, 2021. Details of the presentations are outlined below.
2021-09-30 18:20:00 - PRNewsWire
SHAREHOLDER ALERT: WeissLaw LLP Reminds CXP, JMP, ECHO, and KDMN Shareholders About Its Ongoing Investigations
NEW YORK, Sept. 30, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq.
2021-09-30 11:08:25 - Zacks Investment Research
3 Big Drug/Biotech Stocks to Boost Your Portfolio's Health
Sanofi (SNY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that are worth betting on in the current scenario.
2021-09-13 15:17:00 - PRNewsWire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Kadmon Holdings, Inc. - KDMN
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Kadmon Holdings, Inc. ("KDMN" or the "Company") (KDMN) relating to its proposed acquisition by Sanofi.
2021-09-09 01:20:00 - Business Wire
Kadmon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Kadmon Holdings, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – KDMN
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Kadmon Holdings, Inc. (NASDAQ: KDMN) to Sanofi for $9.50 per share in cash is fair to Kadmon shareholders. Halper Sadeh encourages Kadmon shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Kadmon and its boa
2021-09-08 20:54:13 - Pulse2
KDMN Stock: Why It Surged Today
The stock price of Kadmon Holdings Inc (NASDAQ: KDMN) increased 71.13% today. This is why it The post KDMN Stock: Why It Surged Today appeared first on Pulse 2.0.
2021-09-08 12:30:00 - PRNewsWire
Shareholder Alert: Ademi LLP investigates whether Kadmon Holdings, Inc. has obtained a Fair Price in its transaction with Sanofi
MILWAUKEE, Sept. 8, 2021 /PRNewswire/ -- Ademi LLP is investigating Kadmon (NASDAQ:KDMN), for possible breaches of fiduciary duty and other violations of law in its transaction with Sanofi.
2021-09-08 11:00:16 - Zacks Investment Research
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.